More than 4,000 people across the medtech sector met in Boston for one of the industry’s biggest events of the year. Catch up on all the conference news in MedTech Dive’s roundup.
At one of the largest medical device events of the year, attendees met to discuss the latest developments in a year marked by high-profile cyberattacks and questions about artificial intelligence regulations.
At AdvaMed’s The MedTech Conference, more than 4,000 company leaders, regulators and innovators met in Boston.
Hot topics included AI, cybersecurity, M&A, supply chain and a challenging economy. Medtech executives said to expect more portfolio trimming and tuck-in acquisitions as companies face limited resources. They also shared how they are retooling their supply chains amid on-and-off tariffs.
Meanwhile, device leaders with the Food and Drug Administration signaled that medtech firms should watch for guidance on generative AI, and shared an update on hiring for the Center for Devices and Radiological Health and other priorities.
Dr. Michelle Tarver said the FDA’s device center is filling positions after losing large numbers of clinical reviewers, as well as AI and digital health experts. Read the full article ➔
As medical device makers face “finite” capital, portfolio reshaping will likely remain a focus in the sector. Read the full article ➔
Rick Abramson, director of the FDA’s Digital Health Center of Excellence, said to expect draft guidance in the coming months. Read the full article ➔
ResMed CEO Mick Farrell, chair of AdvaMed’s board, said the group plans to come up with standards around privacy, cybersecurity and interoperability.
Source link
